7541-04-0 Usage
Uses
Used in Organic Synthesis:
(Z)-N-(tosyloxy)benzimidoyl cyanide is used as a reagent in organic reactions for introducing the benzimidoyl cyanide moiety into other molecules. Its ability to react with a variety of functional groups allows for the creation of diverse chemical structures, enhancing the compound's versatility in organic synthesis.
Used in Chemical Research:
In the field of chemical research, (Z)-N-(tosyloxy)benzimidoyl cyanide serves as a valuable tool for studying the properties and reactions of various organic compounds. Its unique structure and reactivity contribute to a deeper understanding of chemical interactions and the development of new synthetic methods.
Used in Pharmaceutical Compound Synthesis:
(Z)-N-(tosyloxy)benzimidoyl cyanide is employed as a key building block in the synthesis of pharmaceutical compounds. Its incorporation into these molecules can lead to the development of new drugs with potential therapeutic applications.
Used in Natural Product Synthesis:
(Z)-N-(tosyloxy)benzimidoyl cyanide is also used in the synthesis of natural products, where its reactivity and structural features enable the creation of complex natural compounds with potential biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 7541-04-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,5,4 and 1 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 7541-04:
(6*7)+(5*5)+(4*4)+(3*1)+(2*0)+(1*4)=90
90 % 10 = 0
So 7541-04-0 is a valid CAS Registry Number.
7541-04-0Relevant academic research and scientific papers
PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
-
Paragraph 00632, (2014/06/11)
Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS
-
Page/Page column 173, (2011/02/24)
Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
